Novo Nordisk/X
Aug 2, 2025, 03:50
FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
Novo Nordisk US has shared a proud post on X:
“PRESS: Novo Nordisk receives US FDA approval for a new indication for a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. ”
To learn more, follow the link.
Stay informed with Hemostasis Today.
-
Jan 11, 2026, 06:18Filippo Cademartiri on Why Vascular Health Is Cognitive Health
-
Jan 11, 2026, 06:01Maira Dastgir N on Cannabis-Induced Ischemic Stroke
-
Jan 11, 2026, 05:51Nishant K Mishra on Preventing Post-Stroke Seizures
-
Jan 11, 2026, 05:41Indunil Karunarathna on CSF Xanthochromia in SAH
-
Jan 11, 2026, 05:22Mitchell Elkind on The New York Times Brain Health Challenge: Food Is Brain Medicine!
-
Jan 11, 2026, 03:55Building Better Care for Bleeding Disorders in Zambia․ Chatowa’s Journey
-
Jan 11, 2026, 03:54Unsupervised Machine Learning for Patient Stratification in Cardiovascular Disease
-
Jan 11, 2026, 03:54DAPT De-escalation After PCI․ Where Do We Stand Today?
-
Jan 11, 2026, 03:53Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia